ReviewFrontiers in oncology2025
Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating oncolytic adenoviruses into combination cancer therapy: Mechanisms, advances and clinical outlook.Clinical and translational medicine · 2026Review
- Emerging innovative immunotherapies in malignant ascites: current landscape, challenges and perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: H101 (recombinant human adenovirus type 5) has favorable efficacy and safety in cancer patients with malignant ascites (MA) or pleural effusion (MPE). However, a comprehensive evaluation has not yet been conducted. This meta-analysis aimed to comprehensively investigate the efficacy and safety of H101 in these patients. Methods: The meta-analysis was registered on PROSPERO (ID: CRD420251052407). A comprehensive study search was conducted in PubMed, Web of Science, Cochrane Library, Wan Fang, CNKI, and SinoMed until October 2024. Studies reporting on the remission and safety results in cancer patients with MA/MPE treated with H101 were screened. The overall remission rates (ORRs) of ascites or pleural effusion and adverse reactions were analyzed. Results: A total of 13 studies involving 993 patients were included. The pooled ORR was 69.9% (95%CI = 63.5%-76.4%). The pooled rates of fever, nausea or vomiting, and leukopenia were 22.5% (95%CI = 10.2%-34.9%), 14.0% (95%CI = 6.8%-21.2%), and 24.3% (95%CI = 9.6%-39.1%), respectively. Subgroup analysis revealed that the ORR was higher in studies with a single cancer type than in those with multiple cancer types ( Conclusion: H101 is effective and safe for the treatment of MA/MPE in patients with cancer and may be a promising modality for their clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.